- Omvoh (mirikizumab-mrkz) maintained steroid-free remission in over 90% of Crohn's patients for three years.
- The VIVID-2 study showed low surgery and hospitalization rates in Omvoh-treated patients.
- Omvoh is the first IL-23p19 inhibitor with strong efficacy over four years in UC and three years in Crohn's.
- Common adverse events included COVID-19, nasopharyngitis, and upper respiratory tract infection.
Study Findings
New data from Eli Lilly's VIVID-2 study revealed that over 90% of Crohn's disease patients who achieved steroid-free remission at one year maintained it through three years with Omvoh (mirikizumab-mrkz). The study also highlighted low surgery and hospitalization rates in patients treated with Omvoh for both Crohn's disease and ulcerative colitis (UC).
Long-Term Efficacy
Omvoh is the first IL-23p19 inhibitor to demonstrate strong and durable efficacy over four years in UC and three years in Crohn's disease. Patients who achieved an endoscopic response at one year continued to experience clinical and corticosteroid-free remission, along with sustained bowel urgency improvements, through three years of continuous treatment.
Symptom Relief
In the VIVID-2 study, more than 90% of patients maintained steroid-free remission, and 80% experienced relief from disruptive symptoms like bowel urgency. This provides confidence in Omvoh's ability to deliver lasting outcomes for Crohn's disease patients.
Safety Profile
The long-term safety profile of Omvoh in patients with moderately to severely active Crohn's disease was consistent with known data. Common adverse events reported from the end of year one through the end of year three included COVID-19, nasopharyngitis, and upper respiratory tract infection, affecting 5% or more of patients who achieved an endoscopic response at one year.
